It still irks me that they are selecting 4 endpoints out of the 9 they tested when presenting the data. They had the opportunity to use the same or similar endpoint(s).
"Neurotech examined a large number of anchors (sub-domains) to further understand which important sub-domains benefits NTI164 improved that could be targeted in registration-directed trials. In late-stage clinical trials, typically 2-3 subdomains are typically examined for CGI-I"
This statement doesn't track IMO. I think they will have issues with a registrational trial with those sub domains.
NTI Price at posting:
6.6¢ Sentiment: Hold Disclosure: Held
